Formation of Fe(III) Ternary Complexes with Related Bio-relevant Ligands

Hosny, Wafaa M.

doi:10.5772/intechopen.69158

Cited by 2 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The viability effect is somewhat dependent on the increase in the 5-FU concentration. Taking into consideration that both of the compounds possess anticancer properties [51], there must be a mechanism in which the 5-FU is neutralized by the iron (III)-EDTA complex [58]. A possible reason for this is the formation of the 5-FU-iron(III)-EDTA complex [58].…”

Section: Discussionmentioning

confidence: 99%

“…Taking into consideration that both of the compounds possess anticancer properties [51], there must be a mechanism in which the 5-FU is neutralized by the iron (III)-EDTA complex [58]. A possible reason for this is the formation of the 5-FU-iron(III)-EDTA complex [58]. The other possibility is that the enhancement of the 5-FU-neutralizing enzymes by the iron (III)-EDTA complex occurs.…”

Section: Discussionmentioning

confidence: 99%

“…The other possibility is that the enhancement of the 5-FU-neutralizing enzymes by the iron (III)-EDTA complex occurs. Thus far, other research has proven the formation of an Fe 3+ -EDTA-uracil complex, but further studies should be conducted in this field to investigate the formation of the Fe 3+ -EDTA-5-FU complex [58].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

The Antagonistic and Synergistic Role of Fe3+ Compounds in Chemo- and Electrochemotherapy in Human Colon Cancer In Vitro

Szlasa,

Mazurek,

Szewczyk

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Colon cancer (CC) management includes surgery, radio- and chemotherapy based on treatment with 5-fluorouracil (5-FU) or its derivatives. However, its application is limited to low-grade carcinomas. Thus, much research has been conducted to introduce new techniques and drugs to the therapy. CC mostly affects older people suffering from cardiac diseases, where iron compounds are commonly used. Ferric citrate and iron (III)–EDTA complexes have proven to be effective in colon cancer in vitro. This study aimed to determine the potency and action of iron-containing compounds in colon cancer treatment by chemo- and electrochemotherapy in both nano- and microsecond protocols. The viability of the cells was assessed after standalone iron (III) citrate and iron (III)–EDTA incubation. Both compounds were also assessed with 5-FU to determine the combination index. Additionally, frataxin expression was taken as the quantitative response to the exposition of iron compounds. Each of the substances exhibited a cytotoxic effect on the LoVo cell line. Electroporation with standalone drugs revealed the potency of 5-FU and iron(III)–EDTA in CC treatment. The combination of 5-FU with iron(III)–EDTA acted synergistically, increasing the viability of the cells in the nanosecond electrochemotherapy protocol. Iron(III)–EDTA decreased the frataxin expression, thus inducing ferroptosis. Iron(III) citrate induced the progression of cancer; therefore, it should not be considered as a potential therapeutic option. The relatively low stability of iron(III) citrate leads to the delivery of citrate anions to cancer cells, which could increase the Krebs cycle rate and promote progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Antagonistic and Synergistic Role of Fe3+ Compounds in Chemo- and Electrochemotherapy in Human Colon Cancer In Vitro

Szlasa,

Mazurek,

Szewczyk

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

New Iron(III)-Containing Composite of Salinomycinic Acid with Antitumor Activity—Synthesis and Characterization

Ivanova,

Kukeva,

Stoyanova

et al. 2024

Inorganics

View full text Add to dashboard Cite

In this study we demonstrated for the first time synthetic procedures for composites of salinomycin (SalH) and two-line ferrihydrite. The products were characterized by various methods such as elemental analysis, attenuated total reflectance–Fourier-transform spectroscopy (ATR-FTIR), electron paramagnetic resonance spectroscopy (EPR), powder X-ray diffraction analysis (XRD), electrospray-ionization mass spectrometry (ESI-MS), thermogravimetric analysis with differential thermal analysis (DTA) and mass spectrometry (TG-DTA/MS). The EPR spectra of the isolated compounds consisted of signals associated with both isolated Fe3+ ions and magnetically coupled Fe3+ ions. Powder XRD analyses of the isolated products showed two intense and broad peaks at 9° and 15° 2Θ, corresponding to salinomycinic acid. Broad peaks with very low intensity around 35°, assigned to two-line ferrihydrite, were also registered. Based on the experimental results, we concluded that salinomycin sodium reacted with Fe(III) chloride to form composites consisting of two-line ferrihydrite and salinomycinic acid. One of the composites exerted pronounced antitumor activity in the sub-micromolar concentration range against human cervical cancer (HeLa), non-small-cell lung cancer (A549), colon cancer (SW480), and ovarian teratocarcinoma (CH1/PA1) cells.

show abstract

Formation of Fe(III) Ternary Complexes with Related Bio-relevant Ligands

Abstract: Ternary complexes of iron(III)-glycine( Gly)-nitrilotriacetate (NTA) system determined by electrochemical measurements of the dissolved iron(III)-Gly-NTA mixed ligand system in the 0.1 molÁdm

Cited by 2 publications

References 38 publications

The Antagonistic and Synergistic Role of Fe3+ Compounds in Chemo- and Electrochemotherapy in Human Colon Cancer In Vitro

The Antagonistic and Synergistic Role of Fe3+ Compounds in Chemo- and Electrochemotherapy in Human Colon Cancer In Vitro

New Iron(III)-Containing Composite of Salinomycinic Acid with Antitumor Activity—Synthesis and Characterization

Contact Info

Product

Resources

About